Literature DB >> 11069986

Characterization of human herpesvirus 8 ORF59 protein (PF-8) and mapping of the processivity and viral DNA polymerase-interacting domains.

S R Chan1, B Chandran.   

Abstract

Human herpesvirus 8 (HHV-8) or Kaposi's sarcoma-associated herpesvirus (KSHV) ORF59 protein (PF-8) is a processivity factor for HHV-8 DNA polymerase (Pol-8) and is homologous to processivity factors expressed by other herpesviruses, such as herpes simplex virus type 1 UL42 and Epstein-Barr virus BMRF1. The interaction of UL42 and BMRF1 with their corresponding DNA polymerases is essential for viral DNA replication and the subsequent production of infectious virus. Using HHV-8-specific monoclonal antibody 11D1, we have previously identified the cDNA encoding PF-8 and showed that it is an early-late gene product localized to HHV-8-infected cell nuclei (S. R. Chan, C. Bloomer, and B. Chandran, Virology 240:118-126, 1998). Here, we have further characterized PF-8. This viral protein was phosphorylated both in vitro and in vivo. PF-8 bound double-stranded DNA (dsDNA) and single-stranded DNA independent of DNA sequence; however, the affinity for dsDNA was approximately fivefold higher. In coimmunoprecipitation reactions, PF-8 also interacted with Pol-8. In in vitro processivity assays with excess poly(dA):oligo(dT) as a template, PF-8 stimulated the production of elongated DNA products by Pol-8 in a dose-dependent manner. Functional domains of PF-8 were determined using PF-8 truncation mutants. The carboxyl-terminal 95 amino acids (aa) of PF-8 were dispensable for all three functions of PF-8: enhancing processivity of Pol-8, binding dsDNA, and binding Pol-8. Residues 10 to 27 and 279 to 301 were identified as regions critical for the processivity function of PF-8. Interestingly, aa 10 to 27 were also essential for binding Pol-8, whereas aa 1 to 62 and aa 279 to 301 were involved in binding dsDNA, suggesting that the processivity function of PF-8 is correlated with both the Pol-8-binding and the dsDNA-binding activities of PF-8.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11069986      PMCID: PMC113171          DOI: 10.1128/jvi.74.23.10920-10929.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group.

Authors:  D F Martin; B D Kuppermann; R A Wolitz; A G Palestine; H Li; C A Robinson
Journal:  N Engl J Med       Date:  1999-04-08       Impact factor: 91.245

2.  A protein kinase activity associated with Epstein-Barr virus BGLF4 phosphorylates the viral early antigen EA-D in vitro.

Authors:  M R Chen; S J Chang; H Huang; J Y Chen
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 3.  Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8).

Authors:  T F Schulz
Journal:  J Gen Virol       Date:  1998-07       Impact factor: 3.891

Review 4.  KSHV and Kaposi's sarcoma: the end of the beginning?

Authors:  D Ganem
Journal:  Cell       Date:  1997-10-17       Impact factor: 41.582

5.  Identification and characterization of human herpesvirus-8 lytic cycle-associated ORF 59 protein and the encoding cDNA by monoclonal antibody.

Authors:  S R Chan; C Bloomer; B Chandran
Journal:  Virology       Date:  1998-01-05       Impact factor: 3.616

6.  Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) open reading frame 36 protein is a serine protein kinase.

Authors:  J Park; D Lee; T Seo; J Chung; J Choe
Journal:  J Gen Virol       Date:  2000-04       Impact factor: 3.891

7.  Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases.

Authors:  G Rezza; M Andreoni; M Dorrucci; P Pezzotti; P Monini; R Zerboni; B Salassa; V Colangeli; L Sarmati; E Nicastri; M Barbanera; R Pristerà; F Aiuti; L Ortona; B Ensoli
Journal:  J Natl Cancer Inst       Date:  1999-09-01       Impact factor: 13.506

Review 8.  Kaposi's sarcoma: a result of the interplay among inflammatory cytokines, angiogenic factors and viral agents.

Authors:  B Ensoli; M Stürzl
Journal:  Cytokine Growth Factor Rev       Date:  1998-03       Impact factor: 7.638

9.  Human herpesvirus-8 ORF K8.1 gene encodes immunogenic glycoproteins generated by spliced transcripts.

Authors:  B Chandran; C Bloomer; S R Chan; L Zhu; E Goldstein; R Horvat
Journal:  Virology       Date:  1998-09-15       Impact factor: 3.616

10.  Herpes simplex virus processivity factor UL42 imparts increased DNA-binding specificity to the viral DNA polymerase and decreased dissociation from primer-template without reducing the elongation rate.

Authors:  K Weisshart; C S Chow; D M Coen
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

View more
  36 in total

1.  Specific residues in the connector loop of the human cytomegalovirus DNA polymerase accessory protein UL44 are crucial for interaction with the UL54 catalytic subunit.

Authors:  Arianna Loregian; Brent A Appleton; James M Hogle; Donald M Coen
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

2.  Interaction of Kaposi's sarcoma-associated herpesvirus ORF59 with oriLyt is dependent on binding with K-Rta.

Authors:  Cyprian C Rossetto; Ni Ketut Susilarini; Gregory S Pari
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

3.  Octamer-binding sequence is a key element for the autoregulation of Kaposi's sarcoma-associated herpesvirus ORF50/Lyta gene expression.

Authors:  S Sakakibara; K Ueda; J Chen; T Okuno; K Yamanishi
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Downregulation of Poly(ADP-Ribose) Polymerase 1 by a Viral Processivity Factor Facilitates Lytic Replication of Gammaherpesvirus.

Authors:  Woo-Chang Chung; Joo-Hee Park; Hye-Ri Kang; Moon Jung Song
Journal:  J Virol       Date:  2015-07-08       Impact factor: 5.103

5.  The crystal structure of PF-8, the DNA polymerase accessory subunit from Kaposi's sarcoma-associated herpesvirus.

Authors:  Jennifer L Baltz; David J Filman; Mihai Ciustea; Janice Elaine Y Silverman; Catherine L Lautenschlager; Donald M Coen; Robert P Ricciardi; James M Hogle
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

6.  Kaposi's Sarcoma-Associated Herpesvirus Deregulates Host Cellular Replication during Lytic Reactivation by Disrupting the MCM Complex through ORF59.

Authors:  Roxanne Strahan; Prerna Dabral; Kammi Dingman; Christian Stadler; Kayla Hiura; Subhash C Verma
Journal:  J Virol       Date:  2018-10-29       Impact factor: 5.103

7.  The FAT10 post-translational modification is involved in the lytic replication of Kaposi's sarcoma-associated herpesvirus.

Authors:  Atsuko Sugimoto; Yuichi Abe; Tadashi Watanabe; Kohei Hosokawa; Jun Adachi; Takeshi Tomonaga; Yasumasa Iwatani; Takayuki Murata; Masahiro Fujimuro
Journal:  J Virol       Date:  2021-02-24       Impact factor: 5.103

8.  Inhibition of infection and replication of human herpesvirus 8 in microvascular endothelial cells by alpha interferon and phosphonoformic acid.

Authors:  Laurie T Krug; Veronika P Pozharskaya; Yimin Yu; Naoki Inoue; Margaret K Offermann
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

9.  Kaposi's sarcoma-associated herpesvirus RTA activates the processivity factor ORF59 through interaction with RBP-Jkappa and a cis-acting RTA responsive element.

Authors:  Yunhua Liu; Yajun Cao; Deguang Liang; Yuan Gao; Tian Xia; Erle S Robertson; Ke Lan
Journal:  Virology       Date:  2008-09-10       Impact factor: 3.616

10.  The ORF59 DNA polymerase processivity factor homologs of Old World primate RV2 rhadinoviruses are highly conserved nuclear antigens expressed in differentiated epithelium in infected macaques.

Authors:  A Gregory Bruce; Angela M Bakke; Courtney A Gravett; Laura K DeMaster; Helle Bielefeldt-Ohmann; Kellie L Burnside; Timothy M Rose
Journal:  Virol J       Date:  2009-11-18       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.